Patents by Inventor Cassandra Celatka

Cassandra Celatka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KDM1A inhibitors for the treatment of disease
    Patent number: 11932629
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: March 19, 2024
    Assignee: Imago Biosciences, Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Michael Clare, Hugh Y. Rienhoff, Jr.
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11773068
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: October 3, 2023
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A
    Publication number: 20230293495
    Abstract: Provided is a pharmaceutical composition comprising: N—((S)-5-((1R,2S)-2-(4-fluorophenyl)cyclopropylamino)-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl)-4-(1H-1,2,3-triazol-1-yl)benzamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one stabilizer, pharmaceutical preparations thereof, and methods for the treatment a disease or disorder associated with KDM1A activity.
    Type: Application
    Filed: March 23, 2023
    Publication date: September 21, 2023
    Inventors: Amy TAPPER, Cassandra CELATKA, Patricia SOULLIAC, Parag VED, Namrata VORA
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20230250090
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Application
    Filed: December 15, 2022
    Publication date: August 10, 2023
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, JR.
  • METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS
    Publication number: 20230104647
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive amination of cyclopropylamines.
    Type: Application
    Filed: June 15, 2022
    Publication date: April 6, 2023
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11578059
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 14, 2023
    Assignee: Imago Biosciences. Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Michael Clare, Hugh Y. Rienhoff, Jr.
  • Methods and processes for the preparation of KDM1A inhibitors
    Patent number: 11390590
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: July 19, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Arthur Glenn Romero, John M. McCall, Toni Chancellor, Jian-Xie Chen, Xuemei Chen, He Zhao, Betina Biolatto, Elisabeth C. A. Brot, Zhihua Li, Xiaoming Liao
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20220073508
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Application
    Filed: April 14, 2021
    Publication date: March 10, 2022
    Applicant: Genzyme Corporation
    Inventors: Elyse BOURQUE, Mario A. CABRERA-SALAZAR, Cassandra CELATKA, Seng H. CHENG, Bradford HIRTH, Andrew GOOD, Katherine JANCSICS, John MARSHALL, Markus METZ, Ronald K. SCHEULE, Renato SKERLJ, Yibin XIANG, Zhong ZHAO, John LEONARD, Thomas NATOLI, Elina MAKINO, Herve HUSSON, Oxana BESKROVNAYA
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20220073477
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 10, 2022
    Inventors: Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE AMINOCYCLOPROPANES
    Publication number: 20220025424
    Abstract: The present disclosure relates to compositions and methods for producing stereoisomerically pure aminocyclopropanes.
    Type: Application
    Filed: August 16, 2017
    Publication date: January 27, 2022
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, He ZHAO, Betina BIOLATTO, Jian-Xie CHEN, Elisabeth C.A. BROT, Peter C. MICHELS, Venkat K. CHARI, Ian C. COTTERILL
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11230534
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: January 25, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20210261557
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: April 27, 2021
    Publication date: August 26, 2021
    Applicant: GENZYME CORPORATION
    Inventors: Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
  • Glucosylceramide synthase inhibitors
    Patent number: 11008316
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS), such as Compound of Formula I, shown below, as defined herein, useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: May 18, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Elyse Bourque, Mario A. Cabrera-Salazar, Cassandra Celatka, Seng H. Cheng, Bradford Hirth, Andrew Good, Katherine Jancsics, John Marshall, Markus Metz, Ronald K. Scheule, Renato Skerlj, Yibin Xiang, Zhong Zhao, John Leonard, Thomas Natoli, Elina Makino, Herve Husson, Oxana Beskrovnaya
  • METHODS AND PROCESSES FOR THE PREPARATION OF KDM1A INHIBITORS
    Publication number: 20210139437
    Abstract: Provided in this disclosure are methods for the synthesis of substituted 2-arylcyclopropylamines and 2-heteroarylcyclopropylamines and related compounds. Also provided are methods for reduction of thioesters to aldehydes, and methods for reductive animation of cyclopropylamines.
    Type: Application
    Filed: August 16, 2017
    Publication date: May 13, 2021
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Arthur Glenn ROMERO, John M. MCCALL, Toni CHANCELLOR, Jian-Xie CHEN, Xuemei CHEN, He ZHAO, Betina BIOLATTO, Elisabeth C.A. BROT, Zhihua LI, Xiaoming LIAO
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20210115023
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1 A for the treatment or prevention of diseases. Methods of inhibition of KDM1 A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 22, 2021
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, Jr.
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20200283397
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: November 1, 2019
    Publication date: September 10, 2020
    Inventors: Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
    Publication number: 20200048266
    Abstract: The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.
    Type: Application
    Filed: August 15, 2019
    Publication date: February 13, 2020
    Inventors: Elyse BOURQUE, Mario CABRERA-SALAZAR, Cassandra CELATKA, Seng CHENG, Mary A. CROMWELL, Andrew GOOD, Bradford HIRTH, Katherine JANCSICS, John P. LEONARD, Lingyun LI, James LILLIE, Hanlan LIU, Elina MAKINO, John MARSHALL, Paul MASON, Markus METZ, Fazeela MORSHED, Thomas O'SHEA, Ronald SCHEULE, Renato SKERLJ, Bing WANG, Yibin XIANG, Zhong ZHAO
  • KDM1A inhibitors for the treatment of disease
    Patent number: 10519118
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: December 31, 2019
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20180312474
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: April 12, 2018
    Publication date: November 1, 2018
    Inventors: Hugh Y. RIENHOFF, Jr., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • KDM1A inhibitors for the treatment of disease
    Patent number: 9981922
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 29, 2018
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper